ANGIODYNAMICS $ANGO Q1โ27 EARNINGS HIGHLIGHTS
๐น Revenue: $80.9M (Est. $80.5M) ๐ข; +6.9% YoY
๐น Adj. EPS: -$0.04 (Est. -$0.11) ๐ข
๐น Gross Margin: 59.4%; +410 bps YoY
Affirms FY27 Guide:
๐น Revenue: $336.0M-$341.0M (Est. $337M) ๐ก
๐น Adj. EPS: -$0.29--$0.24 (Est. -$0.27) ๐ก
๐น Adj. EBITDA: $13.0M-$16.0M (Est. $13.8M) ๐ก
๐น Gross Margin: 54% to 55%
๐น Med Tech Growth: 12% to 15%
๐น Med Device Growth: Flat
Cash Flow:
๐น Cash from Operations: $15.3M used
Segment Net Revenue:
๐น Med Tech: $39.9M; +13.2% YoY
๐น Med Device: $41.0M; +1.4% YoY
๐น Auryon: $18.9M; +14.7% YoY
๐น Mechanical Thrombectomy: $12.0M; +6.7% YoY
๐น NanoKnife: $8.3M; +29.0% YoY
Announcements:
๐น CEO: Eric Honroth appointed effective November 2, 2026
๐น FDA IDE approval for the RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia
Other Q1 Metrics:
๐น Adj. EBITDA: $5.0M (Est. $1.3M) ๐ข; +127% YoY
๐น Cash: $34.0M; debt-free balance sheet
Comments:
๐ธ โMed Tech again led our growth, highlighted by Auryon's 21(st) consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.โ
๐ธ โI'm pleased to share that Eric Honroth will become our next President and Chief Executive Officer. He brings the right experience and leadership to build on the foundation we've established, and I will remain closely involved to ensure a smooth transition.โ